$AVTX News

Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38

Avalo Therapeutics To Be Added To Small-Cap Russell 2000 Index And Broad-Market Russell 3000 Index, Effective June 26

Avalo Therapeutics Advances AVTX-010, Long-Acting Next-Gen Anti-IL-1β mAB With Potential For Development In HS And Additional Inflammatory Disorders; IND Submission Planned For H1 2027

B of A Securities Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $35

Avalo Therapeutics: Sell-Off Could Continue If Overall Market Deteriorates Further

Citizens Maintains Market Outperform on Avalo Therapeutics, Lowers Price Target to $55

These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results

Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $34

Mizuho Maintains Outperform on Avalo Therapeutics, Raises Price Target to $45

HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $35

Avalo Therapeutics Q1 EPS $(0.98) Beats $(1.13) Estimate

Piper Sandler Maintains Overweight on Avalo Therapeutics, Raises Price Target to $60

Avalo Therapeutics: Abdakibart Delivers Breakout Phase 2 HS Data

Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results

Citizens Maintains Market Outperform on Avalo Therapeutics, Raises Price Target to $62

Wedbush Maintains Outperform on Avalo Therapeutics, Raises Price Target to $40

BTIG Maintains Buy on Avalo Therapeutics, Raises Price Target to $58

Avalo Therapeutics Launches Common Stock, Pre-Funded Warrants Offering; Terms Undisclosed

Avalo Therapeutics Announces Topline Results From Phase 2 LOTUS Trial Evaluating Efficacy And Safety Of Abdakibart In Adults With Hidradenitis Suppurativa; LOTUS Trial Met Primary Endpoint At Both Doses Studied

BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target